Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06507618 · ClinicalTrials.gov registry record · Phase 3
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
A Phase 3 study of Breast Cancer Female, sponsored by University of Virginia.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 354
- Enrollment target
- 4
- Study locations
NCT06507618: Recruiting Phase 3 study of Breast Cancer Female, sponsored by University of Virginia.
NCT06507618 is a Phase 3 study of Breast Cancer Female that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 354 participants, below the 685-participant average among 46 other Breast Cancer Female trials with a reported enrollment target (48% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06507618, a Phase 3 study of Breast Cancer Female, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 354 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase III, multisite exploratory study for women ≥ 65 years of age with early stage estrogen receptor positive (ER+) breast cancer. These individuals will be treated randomly assigned to one of two groups: Intervention, treated with 3 months of pre-operative endocrine therapy (pre-ET) OR Control, participants follow standard of care and proceed directly to breast cancer surgery. Both arms will be assessed for tolerance and compliance to the endocrine therapy by patient reported outcome (PRO) measures (patient surveys).
Primary Outcome
Proportion of participants who omit RT and are non-adherent to ET as measure through the 24-month adjuvant follow-up visit
Conditions Studied
Interventions
- DRUG Tamoxifen, Letrozole, Anastrozole, or Exemestane
Study Locations (4)
Virginia
- University of Virginia - Charlottesville
- University of Virginia Community Health - Culpeper
- INOVA Schar Cancer - Fairfax
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 354 participants |
| Start Date | 2024-07-19 |
| Est. Completion | 2034-03-01 |
| Phase | Phase 3 |
What NCT06507618 shows while recruiting
NCT06507618 is an interventional study that assigns participants to a tested intervention. The registered 354 participants enrollment target is mid-sized for trials with a published cap, below the 685-participant average among 46 other Breast Cancer Female trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Breast Cancer Female appearing as the primary indexed condition, and to 1 intervention - of which Tamoxifen, Letrozole, Anastrozole, or Exemestane is the first listed.
NCT06507618 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06507618 about?
NCT06507618 is a clinical study titled "Pre-Operative Window of ET to Inform RT Decisions (POWER II)". This is a Phase III, multisite exploratory study for women ≥ 65 years of age with early stage estrogen receptor positive (ER+) breast cancer. These individuals will be treated randomly assigned to one of two groups: Intervention, treated with 3 months of pre-operative endocrine therapy (pre-ET) OR ...
What is the current status of trial NCT06507618?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 354 participants. The study started on 2024-07-19. Estimated completion is 2034-03-01.
What conditions does trial NCT06507618 study?
This clinical trial studies the following conditions: Breast Cancer Female.
What interventions are being tested in trial NCT06507618?
The interventions under investigation include: Tamoxifen, Letrozole, Anastrozole, or Exemestane (DRUG).
Who is sponsoring clinical trial NCT06507618?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06507618 being conducted?
This trial has 4 study locations across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Female
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06507618's enrollment target sits among peer trials
354 10th of 46 higher than 37 of 46 other Breast Cancer Female trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer Female trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
Breast Cancer Resiliency Through Exercise Program (B-REP)
RECRUITING · NA
-
Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02579967 · 354 participants · Phase 2
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- NCT02610413 · 354 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
- NCT05729256 · 354 participants · NA
Alcohol and "Heat of the Moment" Sexual Decision Making
- NCT07133308 · 355 participants · Phase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI